Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 7:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Interventions
Pantoprazole 40 mg IV daily and tube feed., Placebo and tube feed
Drug · Other
Lead sponsor
Mohamed Saad
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Congenital Fibrinogen Deficiency
Interventions
FCH
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Las Vegas, Nevada • Durham, North Carolina
Conditions
Esophageal Varices
Interventions
endoscopic variceal band ligation
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Completed No phase listed Observational Results available

PROPACT: Retrospective Prophylaxis Patient Case Collection

NCT00882778
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Postpartum Hemorrhage
Interventions
Saline delivered using an intrauterine pressure catheter (IUPC)
Combination Product
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more
Conditions
Hemophilia B
Interventions
rFIXFc, FIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more
Conditions
Hypothermia, Anemia
Interventions
Delayed cord clamping
Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 1 Minute
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

NCT00033917
Conditions
Intraventricular Hemorrhage (IVH), Bleeding in the Brain, Prematurity, Very Low Birth Weight Infants
Interventions
indomethacin, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 6 Hours
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut • Portland, Maine • Providence, Rhode Island
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Prevention of Postpartum Hemorrhage With TXA

NCT03326596
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid 1000 mg/10ml normal saline infusion
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 54 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Conditions
Hemophilia A
Interventions
Emicizumab, FVIII
Drug
Lead sponsor
Wayne State University
Other
Eligibility
6 Years to 19 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 6 more
Conditions
Blood Loss, Surgical, Postoperative Hemorrhage
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more
Conditions
Traumatic Brain Injury, Subarachnoid Hemorrhage
Interventions
Levetiracetam, Phenytoin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Scoliosis
Interventions
Tranexamic Acid, Normal Saline, Epsilon aminocaproic acid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Aneurysm, Vasospasm
Interventions
transluminal ballooning, currently existing therapies for the treatment of vasospasm
Procedure · Other
Lead sponsor
University of California, Davis
Other
Eligibility
17 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Sacramento, California • Nashville, Tennessee • Seattle, Washington
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents

NCT03585504
Conditions
Contraceptive Usage
Interventions
Etonogestrel contraceptive implant
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 21 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Obstetrical Complications, Hemorrhage, Labor and Delivery
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
Conditions
Hemophilia A
Interventions
BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 9 more
Terminated Not applicable Interventional Results available

Trial on Endovascular Aneurysm Management

NCT00537134
Conditions
Brain Aneurysm
Interventions
Embolization, coiling
Device
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Boston, Massachusetts • Brooklyn, New York + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of Postpartum Hemorrhage With Tranexamic Acid

NCT03287336
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene in Subarachnoid Hemorrhage

NCT01024972
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Dantrolene, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts